Hungary-based hybrid imaging supplier Mediso has received clearance from the US Food and Drug Administration (FDA) for its InterView FUSION and InterView XP multimodality image processing and reporting software, which is specifically adapted for nuclear medicine and molecular imaging workflows.
The InterView software provides a complete solution for image visualisation, post-processing and reporting specifically adapted for routine nuclear medicine and molecular imaging workflow. It can integrate with any hospital information system either running on a standalone workstation or on a physical or virtualised server.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The software tools offer fast, standardised reporting, covering the most common nuclear medicine areas, including bone, cardiac, central nervous system, thyroid, parathyroid, kidney, liver, digestive system and lung.
There are also state-of-the-art modules to enhance clinical and preclinical research such as automatic lesion detection, automatic segmentation and image denoising.
The software improves SPECT image quality with iterative reconstruction and reaches absolute quantitation with its Tera-Tomo SPECT reconstruction engine, which allows fast and accurate personalised dosimetry.
“Receiving the FDA nod for our image processing software marks the next step in marketing our clinical products in the USA,” said Mediso CEO Istvan Bagamery.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research applications, and they demonstrate our continuous commitment to the molecular imaging market.”
According to a report by GlobalData, the global diagnostic imaging market is set to reach $31.9bn this year and will record steady growth with a compound annual growth rate (CAGR) of 4.8% to reach $45.8bn in 2030. This is mainly driven by a growth in the prevalence of chronic diseases and increased demand for imaging procedures from an ageing population.
Earlier this month, Mediso also deployed its nanoScan 7T magnetic resonance imaging (MRI) system at the University of Milano-Bicocca in Milan, Italy.
